Protagonist Therapeutics’ (PTGX) Outperform Rating Reaffirmed at Wedbush
Wedbush reissued their outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note published on Friday,Benzinga reports. The brokerage currently has a $70.00 price objective on the stock. A number of other research firms have also weighed in on PTGX. BTIG Research set a $73.00 price objective on shares of […]
Wedbush reissued their outperform rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note published on Friday,Benzinga reports. The brokerage currently has a $70.00 price objective on the stock. A number of other research firms have also weighed in on PTGX. BTIG Research set a $73.00 price objective on shares of […]
-limited-logo-1200x675.png?v=20240522095703&w=240&h=240&zc=2){kind=logo}
